Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Debt-to-Equity : 0.62 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals Debt-to-Equity?

Cumberland Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.35 Mil. Cumberland Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.08 Mil. Cumberland Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $29.60 Mil. Cumberland Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cumberland Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

CPIX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.38 Max: 0.62
Current: 0.62

During the past 13 years, the highest Debt-to-Equity Ratio of Cumberland Pharmaceuticals was 0.62. The lowest was 0.02. And the median was 0.38.

CPIX's Debt-to-Equity is ranked worse than
72.8% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs CPIX: 0.62

Cumberland Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Cumberland Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals Debt-to-Equity Chart

Cumberland Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.42

0.41

0.38

0.58

0.62

Cumberland Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.58	0.57	0.51	0.52	0.62

Competitive Comparison of Cumberland Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cumberland Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Debt-to-Equity falls into.

Cumberland Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cumberland Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.348	+	18.08)	/	29.603
	=	0.62

Cumberland Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.348	+	18.08)	/	29.603
	=	0.62

Cumberland Pharmaceuticals (NAS:CPIX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cumberland Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203

Website

https://www.cumberlandpharma.com

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.

Executives

Todd M. Anthony	officer: Vice Pres Organizational Dev	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman	officer: Vice Pres Sales & Marketing	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante	director	111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones	director	2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr	director	850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi	director, 10 percent owner, officer: Chairman and CEO	1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal	director	31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard	officer: Senior Vice President	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs	director	830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence	director	1880 ELLINGTON WAY, AUBURN AL 36830